Navigation Links
BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
Date:10/5/2009

PRINCETON, N.J., Oct. 5 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd. (Otsuka) to provide Otsuka with access to BioWa's POTELLIGENT® Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity (ADCC). BioWa's first Japanese pharmaceutical POTELLIGENT® License was initiated in May, 2007 with Takeda Pharmaceutical Company Limited.

"We are delighted about our partnership with Otsuka, a global healthcare company with a strong tradition in molecular discovery," commented Dr. Masamichi Koike, BioWa's President and CEO. "We are pleased to be in a position to augment Otsuka's impressive pipeline."

Under the terms of the license agreement, BioWa grants Otsuka non-exclusive rights to research, develop and commercialize therapeutic antibodies generated through POTELLIGENT® Technology for an undisclosed number of targets. In return, BioWa will receive an upfront payment, development milestone payments and royalties on products. Other details of the agreement are not disclosed.

About POTELLIGENT® Technology

POTELLIGENT® Technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics. POTELLIGENT® Technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT® Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT® antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owne
'/>"/>

SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...re-FirstCall/--NuVasive,Inc.(Nasdaq: NUVA ),amedic...allydisruptivesurgicaltreatmentsforthespine,announ...mber30,2009,at5:30p.m.ET/2:30p.m.PT.Theconferencec...fortheCompany,sproductsandwillincludecommentsfromm...Thedial-innumbersare1-877-407-4018fordomesticcalle...
(Date:11/25/2009)...OHANNESBURG,November25/PRNewswire/--,iThembaPharma...dtoday,thattheyhavesignedacollaborativeagreementto...,sworldclasscomputationalchemistryandleaddiscovery...ntoprovidemedicinaland,syntheticchemistrysupportto...tnetwork.iThembaPharmaceuticalsandPyxisDiscovery,a...
(Date:11/24/2009)...wire/-- ,, WHAT:RomHoubens,aBelgianmanthoughtto...sactuallyfullyconsciousandawakeduringthattimeandwa...EyeMaxwasfeaturedinthesegmenttoillustratehowpeople...mmunication. ,, WHEN:GoodMorningAmerica-- Tuesd....com ,, WHO:RomHoubenswasanengineeringstude...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2Making bacteria make useful proteins 13871 1Making more efficient fuel cells 9811 1Largest ever Alzheimers genome study unveils dementia mysteries 9809 1Largest ever Alzheimers genome study unveils dementia mysteries 9809 2Largest ever Alzheimers genome study unveils dementia mysteries 9809 3
...ny,(NYSE: LLY ) announced today that the U.S. Foo...lta(R) (duloxetine HCl) for the maintenance,treatm... "Relapse, the re-emergence of depressive symptom... significant clinical concern," says Doug,Williams...Eli Lilly and,Company. "This approval from the FDA...
...il,joins organizations and individuals across the ... annual World AIDS Day, December 1, 2007. Since 19...ties to raise awareness,about the HIV/AIDS pandemi...nd local efforts to stop AIDS., The 2007 and 2008...years since it was first identified, the HIV/AIDS ...
Other Medicine Technology:FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder 4AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic 2
(Date:11/27/2009)...all/--TheGymboreeCorporation(Nasdaq: GYMB )announc...MX23rdInvestorProgram,whichwillbeheldattheMayFairH...11:45a.m.GMT. ,, TolistentoalivebroadcastofTheG...easelogontowww.gymboree.com,clickon"OurCompany"att...ndthen"ConferenceCalls&Webcasts."Thewebcastwil...
(Date:11/27/2009)...e-FirstCall/--ShamirOpticalIndustryLtd.(Nasdaq: SH...ctsandtechnologytotheophthalmiclensmarket,announce...istributioninanaggregateamountofUS$10million(appro...presentativerateofexchange),orapproximatelyUS$0.60...esentativerateofexchange)perordinarysharebasedonth...
(Date:11/27/2009)... economic burdens, study predicts , , FR...ople with diabetes in the United States is expecte...edicts. , That would bring the total by 2034 to...om 23.7 million today. , , At the same time, the..., the study also warns, rising from an estimated $...
(Date:11/27/2009)...gual coloring books designed for children ages 2 t...o educate - inform parents and children alike on a...rs to ABC,S and a host of other topics. , ...27, 2009 -- Today’s children have enough gad...ur of the day, but one of the oldest and simplest ...
(Date:11/26/2009)...ndfluseasonuponus,it,smoreimportantthanevertoemplo...idillness. ,, "Weneedtobeproactivenotonlytokeep...,resick,"saidEileenFinerty,RN,MS,CIC(certifiedinin...landoccupationalhealthatHospitalforSpecialSurgery(...soneofthelowestinfectionratesofanyhospitalinthecou...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...process may improve overall care, researchers say ...atients with heart attacks or other acute heart ev...rates in hospitals that take part in clinical tria...on acute coronary syndrome with unstable angina an...
...e around the world,have had their lives turned ups...s drastic change in their physical appearance was ... generally known as alopecia, which,presently can ... fear of being,ridiculed or rejected., So, imagin...
...nt, PacifiCare denies, CYPRESS, Calif., March 24 ...y members will join the family of Nick Colombo,mar... giant PacifiCare in,Orange County this Tuesday to.../NNOC) announces., The family and the nurses are ...
...ergy &,Anaphylaxis Network (FAAN) will hold its 15...., on March 29, 2008. Many families struggle,with ...Whether attendees,have been living with food aller...,while managing food allergies. Topics will includ...
... Research Hospital have demonstrated that children...ys, can retain normal function in both kidneys by ...aring surgery, even when preoperative scans sugges...racteristics) underwent bilateral nephron-sparing ...
...risk factors with their doctors, SCHAUMBURG, Ill.... a chronic skin condition characterized by thick, ... significant negative impact on a,patient,s overal...-- including cardiovascular disease, depression an...
Other Medicine News:Health News:Patients Do Better at Hospitals With Clinical Trials 2Health News:It's a Bald and Beautiful World 2Health News:Life Denied: Nurses, Family of Sick Teen March on Health Insurance Company Tuesday 2Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in Baltimore 2Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in Baltimore 3Health News:St. Jude study offers new hope for children with kidney tumors deemed inoperable 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 2Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 3Health News:Research Shows Patients With Psoriasis at Increased Risk for Developing Other Serious Medical Conditions 4
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
Medicine Products: